UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Anorexia nervosa in adults: Pharmacotherapy

Author
B Timothy Walsh, MD
Section Editor
Joel Yager, MD
Deputy Editor
David Solomon, MD

INTRODUCTION

Standard treatment for anorexia nervosa consists of nutritional rehabilitation and psychotherapy, and is sometimes augmented with pharmacotherapy [1]. However, there is little evidence supporting the use of medications [1-5]. A few randomized trials suggest that adjunctive antipsychotics may possibly enhance weight gain [6], but other psychotropic drugs have demonstrated little or no benefit in accelerating weight gain or relieving psychological symptoms [1-4].

Psychotropic pharmacotherapy for anorexia nervosa is reviewed here. The clinical manifestations, diagnosis, other treatments and outcome, and medical complications of anorexia nervosa and their management are discussed separately.

(See "Anorexia nervosa in adults: Clinical features, course of illness, assessment, and diagnosis".)

(See "Eating disorders: Overview of treatment".)

(See "Anorexia nervosa in adults and adolescents: Medical complications and their management".)

              

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Jul 19 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. American Psychiatric Association. Treatment of patients with eating disorders,third edition. American Psychiatric Association. Am J Psychiatry 2006; 163:4.
  2. Bulik CM, Berkman ND, Brownley KA, et al. Anorexia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40:310.
  3. Crow SJ, Mitchell JE, Roerig JD, Steffen K. What potential role is there for medication treatment in anorexia nervosa? Int J Eat Disord 2009; 42:1.
  4. Eating Disorders: Core Interventions in the Treatment of and Management of Anorexia Nervosa, Bulimia Nervosa and Related Eating Disorders. National Institute for Clinical Excellence, Clinical Guideline 9. http://guidance.nice.org.uk (Accessed on December 22, 2010).
  5. Attia E. In the clinic. Eating disorders. Ann Intern Med 2012; 156:ITC4.
  6. Kishi T, Kafantaris V, Sunday S, et al. Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Clin Psychiatry 2012; 73:e757.
  7. Halmi KA, Agras WS, Crow S, et al. Predictors of treatment acceptance and completion in anorexia nervosa: implications for future study designs. Arch Gen Psychiatry 2005; 62:776.
  8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
  9. Andersen, AE, Yager, J. Eating disorders. In: Kaplan & Sadock's Comprehensive Textbook of Psychiatry, volume I, ninth edition, Sadock BJ, Sadock VA, Ruiz P (Eds), Lippincott Williams & Wilkins, Philadelphia 2009. p.2128.
  10. Wellbutrin (bupropion hydrochloride) Prescribing Information July 2009 http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103318.htm (Accessed on January 11, 2011).
  11. Sachs KV, Harnke B, Mehler PS, Krantz MJ. Cardiovascular complications of anorexia nervosa: A systematic review. Int J Eat Disord 2016; 49:238.
  12. Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2008; 165:1281.
  13. Attia E, Kaplan AS, Walsh BT, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med 2011; 41:2177.
  14. Claudino AM, Hay P, Lima MS, et al. Antidepressants for anorexia nervosa. Cochrane Database Syst Rev 2006; :CD004365.
  15. Mayer LE. Psychopharmacology of anorexia nervosa and bulimia nervosa. In: Eating Disorders and Obesity, Brownell KD, Walsh BT. (Eds), The Guilford Press, New York. In press.
  16. Phillipou A, Rossell SL, Castle DJ. The neurobiology of anorexia nervosa: a systematic review. Aust N Z J Psychiatry 2014; 48:128.
  17. Walsh BT. The enigmatic persistence of anorexia nervosa. Am J Psychiatry 2013; 170:477.
  18. Kaplan, AS, Howlett, A. Pharmacotherapy for anorexia nervosa. In: The Treatment of Eating Disorders: A Clinical Handbook, Grilo CM, Mitchell JE (Eds), The Guilford Press, New York 2010. p.175.
  19. Dold M, Aigner M, Klabunde M, et al. Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled Trials. Psychother Psychosom 2015; 84:110.
  20. Lebow J, Sim LA, Erwin PJ, Murad MH. The effect of atypical antipsychotic medications in individuals with anorexia nervosa: a systematic review and meta-analysis. Int J Eat Disord 2013; 46:332.
  21. Dunican KC, DelDotto D. The role of olanzapine in the treatment of anorexia nervosa. Ann Pharmacother 2007; 41:111.
  22. Leggero C, Masi G, Brunori E, et al. Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity. J Child Adolesc Psychopharmacol 2010; 20:127.
  23. Kafantaris V, Leigh E, Hertz S, et al. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol 2011; 21:207.
  24. McKnight RF, Park RJ. Atypical antipsychotics and anorexia nervosa: a review. Eur Eat Disord Rev 2010; 18:10.
  25. Hagman J, Gralla J, Sigel E, et al. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adolesc Psychiatry 2011; 50:915.
  26. Powers PS, Klabunde M, Kaye W. Double-blind placebo-controlled trial of quetiapine in anorexia nervosa. Eur Eat Disord Rev 2012; 20:331.
  27. Frank GK. Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa-A case series. Int J Eat Disord 2016; 49:529.
  28. Marzola E, Desedime N, Giovannone C, et al. Atypical antipsychotics as augmentation therapy in anorexia nervosa. PLoS One 2015; 10:e0125569.
  29. Trunko ME, Schwartz TA, Duvvuri V, Kaye WH. Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports. Int J Eat Disord 2011; 44:269.
  30. Steinglass J, Sysko R, Schebendach J, et al. The application of exposure therapy and D-cycloserine to the treatment of anorexia nervosa: a preliminary trial. J Psychiatr Pract 2007; 13:238.
  31. Levinson CA, Rodebaugh TL, Fewell L, et al. D-Cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial. J Clin Psychiatry 2015; 76:e787.
  32. Steinglass JE, Kaplan SC, Liu Y, et al. The (lack of) effect of alprazolam on eating behavior in anorexia nervosa: a preliminary report. Int J Eat Disord 2014; 47:901.
  33. Kaye, WH, Walsh, BT. Psychopharmacology of eating disorders. In: Neuropsychopharmacology: The Fifth Generation of Progress, Davis KL, Charney D, Coyle JT, Nemeroff C (Eds), Lippincott Williams & Wilkins, Philadelphia 2002. p.1675.
  34. Andries A, Frystyk J, Flyvbjerg A, Støving RK. Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. Int J Eat Disord 2014; 47:18.
  35. Walsh BT, Kaplan AS, Attia E, et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA 2006; 295:2605.
  36. Kaplan AS, Walsh BT, Olmsted M, et al. The slippery slope: prediction of successful weight maintenance in anorexia nervosa. Psychol Med 2009; 39:1037.